

IND Number 27073
Sequence No. 0005

December 7, 2020

Marion Gruber, PhD
Director, Office of Vaccines Research and Review
Center for Biologics Evaluation and Research
U.S. Food and Drug Administration
Document Control Center
10903 New Hampshire Avenue
WO71, G112
Silver Spring, MD 20993-0002

Submission Type: Clinical/Safety and Statistics: mRNA-1273-301 Efficacy and Safety Datasets

Dear Dr. Gruber:

Reference is made to pre-assigned submission tracking number (STN) EUA 27073 for Emergency Use Authorization of the new drug mRNA-1273.

The purpose of this submission is to support the Emergency Use Authorization Request submitted on 30 November 2020 for mRNA-1273, a novel lipid nanoparticle (LNP)-encapsulated messenger RNA (mRNA)-based vaccine against the 2019 novel coronavirus (CoV; SARS-CoV-2).

This submission includes:

- Efficacy and safety Analysis and Tabulation datasets (ADaM and SDTM) from the data snapshot dated 25 Nov 2020 for the mRNA-1273-P301 study

If FDA has any questions, please do not hesitate to contact me directly at (b) (6) or at (b) (6)@modernatx.com.

This eCTD submission has been prepared by PPD Development, Inc. in full compliance with ICH and FDA guidance. The eCTD has been verified and confirmed to be virus and spyware free. PPD utilizes Palo Alto Traps v4.2.2. All technical questions should be directed to (b) (6) at PPD (b) (6) or email at (b) (6)

Yours Sincerely,

(b) (6)



200 Technology Square • Cambridge, MA 02139
phone 617-714-6500 • fax 617-649-3744

ModernaTX, Inc.

200 Technology Square

Cambridge, MA 02139

Tel.: (b) (6); Fax: (b) (6)

Email: (b) (6)@modernatx.com